関連する実験動画
Updated: Apr 15, 2026

23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.8K
ダビガトランのアデレンスに関連したサイトレベルの変動と慣行
Supriya Shore1, P Michael Ho2, Anne Lambert-Kerzner3
1Emory University School of Medicine, Atlanta, Georgia.
JAMA
|April 15, 2015
まとめ
患者の選択や薬剤師のモニタリングなどのサイトレベルの実践は,非弁動脈動脈症患者のダビガトランの遵守に大きく影響します. これらの薬剤師主導の介入により,薬剤の服用順守が改善されます.
科学分野:
- 薬理学 薬理学とは
- 医療サービス 研究 医療サービス
- 内科内科は,内科の内科である.
背景:
- ダビガトランのような標的特異的経口抗凝固剤 (TSOAC) は,通常の実験室モニタリングを必要としないため,ワルファリンに優れている.
- しかし,最適なフォローアップ戦略と,ダビガトランの遵守に影響を与えるサイトレベルの要因を理解することは,依然として極めて重要です.
研究 の 目的:
- 異なる医療施設におけるダビガトランの遵守の変動を評価する.
- ダビガトランの遵守の改善と相関する特定のサイトレベルの実践を特定する.
主な方法:
- 復元的な定量データ (67の退役軍人の健康管理局サイト,4863人の患者) と47の薬剤師からの定性データを組み合わせた混合方法のアプローチです.
- 遵守は,カバーされた日数 (PDC) の割合が80%以上であるとして定義されました.
主要な成果:
- ダビガトランの治療の患者遵守の平均値は74%で,サイトレベルの有意な変動がありました (平均オッズ比は1.57).
- 適切な患者選択と薬剤師主導のモニタリングは,より高い遵守率 (RR,1.14および1.25,それぞれ) と関連していました.
- 薬剤師主導の教育は,遵守と統計的に有意な関連性を示さなかった.
結論:
- 医療施設における非弁動脈動脈動脈症患者の間でダビガトランのアデレンスにおいて,著しい変動がある.
- 薬剤師主導の特定の活動,特に患者の選択と継続的なモニタリングの実施は,薬剤の遵守を強化することができます.
関連する概念動画
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Venous Thrombosis III: Interprofessional Care
471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
Venous Thrombosis IV: Nursing Management
397
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
397
Pulmonary Embolism III: Nursing Management
701
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
701
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

